Compare HCA Health Inc (HCA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Neurocrine Biosciences Inc — how do they compare? HCA Health Inc trades at $373.29 (market cap $82.17B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: HCA Health Inc is far larger — about 4.7× Neurocrine Biosciences Inc's market cap, and HCA Health Inc pays a 0.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HCA | NBIX | |
|---|---|---|
Market Cap | $82.17B | $17.40B |
Sector | Health | Health |
52-Week High | $545.13 | $180.55 |
52-Week Low | $334.32 | $123.10 |
Enterprise Value | $131.08B | $16.49B |
Dividend Yield | 0.84% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
